SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Drug Prices and Value for Money
3 references·6 citing·36 second hop
Drug Prices and Value for Money (2005)Drug Prices and Value for MoneyQuality, Innovation, and Value for Money (2005)Quality, Innovation, and Valu…The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (2004)The Medicare Prescription Dru…Problems With the Interpretation of Pharmacoeconomic Analyses (2000)Problems With the Interpretat…An overview of Fintech applications to solve the puzzle of health care funding: state-of-the-art in medical crowdfunding (2022)An overview of Fintech applic…Cost-Utility Analysis of Home-Based Telerehabilitation Compared With Centre-Based Rehabilitation in Patients With Heart Failure (2018)Cost-Utility Analysis of Home…Value in Pharmaceutical Pricing (2013)Value in Pharmaceutical Prici…Preferences for cancer treatments: an overview of methods and applications in oncology (2012)Preferences for cancer treatm…The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond (2008)The Role of Economic Evidence…Measuring Preferences for Cost-Utility Analysis (2007)Measuring Preferences for Cos…The Discovery of Grounded Theory: Strategies for Qualitative Research (1968)The Discovery of Grounded Theory: Strategies for Qualitative Research. (1968)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)National Institute for Clinical Excellence and its value judgments (2004)Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program (2008)The friction cost method for measuring indirect costs of disease (1995)Evidence, hierarchies, and typologies: horses for courses: Table 1 (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) (2017)The Use of Innovative Payment Mechanisms for Gene Therapies in Europe and the USA (2021)Cost-Effectiveness in Health and Medicine (1996)EuroQol: the current state of play (1996)Is The United States Ready For QALYs? (2009)Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD) (2014)Lifestyle Interventions to Prevent Type 2 Diabetes: A Systematic Review of Economic Evaluation Studies (2016)A New Approach to Consumer Theory (1966)Multicriteria decision analysis in oncology (2014)Theory of games and economic behavior (2019)Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature (1992)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Common Methodological Flaws in Economic Evaluations (2005)The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 (2008)EuroQol - a new facility for the measurement of health-related quality of life (1990)Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility (2004)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Towards a Methodology for Developing Evidence‐Informed Management Knowledge by Means of Systematic Review (2003)Crowdfunding: Tapping the right crowd (2013)The dynamics of crowdfunding: An exploratory study (2013)Digital entrepreneurial intentions and actions in China during the COVID-19 pandemic with policy implications (2023)Fintech Innovation in Social Service Provision: A Bibliometric Review (2023)FinTech and the Level of Its Adoption in Different Countries Around the World (2025)EBM, HTA, and CER: Clearing the Confusion (2010)Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part I. Basic Considerations (2010)Patient Protection and Affordable Care Act of 2010: Reforming the Health Care Reform for the New Decade (2011)
this work references cited by second hop

References

  • 2000Problems With the Interpretation of Pharmacoeconomic Analyses224 cited
  • 2004The Medicare Prescription Drug, Improvement, and Modernization Act of 2003206 cited
  • 2005Quality, Innovation, and Value for Money160 cited

Cited by

  • 2013Value in Pharmaceutical Pricing115 cited
  • 2007Measuring Preferences for Cost-Utility Analysis113 cited
  • 2012Preferences for cancer treatments: an overview of methods and applications in oncology111 cited
  • 2008The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond110 cited
  • 2018Cost-Utility Analysis of Home-Based Telerehabilitation Compared With Centre-Based Rehabilitation in Patients With Heart Failure80 cited
  • 2022An overview of Fintech applications to solve the puzzle of health care funding: state-of-the-art in medical crowdfunding24 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work